Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Loperamide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 known ✓ | P35372 | 9/20 | 0.92 |
| ▸ | DRD4 | P21917 | 4/20 | 0.92 |
| ▸ | ADRA2A | P08913 | 3/20 | 0.92 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.92 |
| ▸ | MEN1 | O00255 | 2/20 | 0.92 |
| ▸ | LMNA | P02545 | 2/20 | 0.92 |
| ▸ | ADRB2 | P07550 | 2/20 | 0.92 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.92 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.92 |
| ▸ | HTR2B | P41595 | 2/20 | 0.92 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.92 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.92 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.92 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.92 |
| ▸ | HRH2 | P25021 | 2/20 | 0.92 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.92 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.92 |
| ▸ | SCN5A | Q14524 | 2/20 | 0.92 |
| ▸ | SCN1A | P35498 | 2/20 | 0.92 |
| ▸ | SCN2A | Q99250 | 2/20 | 0.92 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Loperamide SCHEMBL8409779 | 0.96 | OPRM1 (1.00) | OPRM1DRD4ADRA2ASLC6A4MEN1 | |
| Loperamide SCHEMBL12387663 | 0.96 | OPRM1 (1.00) | OPRM1DRD4ADRA2ASLC6A4MEN1 | |
| Loperamide SCHEMBL28530 | 0.96 | OPRM1 (1.00) | OPRM1DRD4ADRA2ASLC6A4MEN1 | |
| Loperamide SCHEMBL9068543 | 0.95 | OPRM1 (1.00) | OPRM1DRD4ADRA2ASLC6A4MEN1 | |
| Loperamide SCHEMBL21327979 | 0.95 | OPRM1 (1.00) | OPRM1DRD4ADRA2ASLC6A4MEN1 | |
| Loperamide SCHEMBL15048 | 0.95 | OPRM1 (1.00) | OPRM1DRD4ADRA2ASLC6A4MEN1 | |
| Loperamide SCHEMBL8409268 | 0.95 | OPRM1 (1.00) | OPRM1DRD4ADRA2ASLC6A4MEN1 | |
| Loperamide SCHEMBL2346867 | 0.94 | OPRM1 (0.98) | OPRM1DRD4ADRA2ASLC6A4MEN1 | |
| Loperamide SCHEMBL542589 | 0.94 | OPRM1 (0.96) | OPRM1DRD4ADRA2ASLC6A4MEN1 | |
| Loperamide SCHEMBL5084617 | 0.93 | OPRM1 (0.94) | OPRM1DRD4ADRA2ASLC6A4MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130071474-A1 | COMBINATIONS OF BERBERINE, ARTEMISININ, Loperamide AND THEIR DERIVATIVES TO TREAT MALARIA, DIARRHEA, TRAVELERS' DIARRHEA, DYSENTERY, DENGUE FEVER, PARASITES, CHOLERA AND VIRUSES | Spencer, James (US) | 2013-03-21 | — | — | US | claimed |
| WO-2012108892-A1 | COMBINATIONS OF BERBERINE, ARTEMISININ, LOPERAMIDE AND THEIR DERIVATIVES TO TREAT MALARIA, DIARRHEA, TRAVELERS' DIARRHEA, DYSENTERY, DENGUE FEVER, PARASITES, CHOLERA AND VIRUSES | SEUBERT KIRK (US) | 2012-08-16 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130071474-A1 | COMBINATIONS OF BERBERINE, ARTEMISININ, Loperamide AND THEIR DERIVATIVES TO TREAT MALARIA, DIARRHEA, TRAVELERS' DIARRHEA, DYSENTERY, DENGUE FEVER, PARASITES, CHOLERA AND VIRUSES | ABCB11, ABCB1, VIP | OPRM1 2792/4885DRD4 2600/4885ADRA2A 588/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.